SATURDAY, July 22, 2023 (HealthDay News) -- In a report from the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines, published online July 20 in Circulation and in the Journal of the American College of Cardiology, recommendations are presented for the diagnosis and management of chronic coronary disease (CCD).
Salim S. Virani, M.D., Ph.D., from the Baylor College of Medicine in Houston, and colleagues conducted a comprehensive literature review to update and consolidate recent evidence relating to the diagnosis and management of patients with stable ischemic heart disease.
The authors highlight team-based, patient-centered care, which takes into account social determinants of health and associated costs, and also includes shared decision-making in risk assessment, testing, and treatment. All patients with CCD are advised to undergo nonpharmacologic therapies, including adopting healthy dietary habits and engaging in exercise. Patients with CCD without contraindications are encouraged to participate in regular physical activity; cardiac rehabilitation provides significant cardiovascular benefits for eligible patients. For select groups of patients with CCD, such as those without diabetes, the use of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists is recommended. New guidelines have been developed for the use of beta blockers in CCD. Statins continue to be the first-line therapy for lipid lowering in CCD; several adjunctive therapies may be used in specific populations. In many situations, shorter durations of dual antiplatelets are considered safe and effective. Nonprescription or dietary supplements are not recommended for CCD.
"Our understanding of the role of social determinants of health, shared decision-making, and the importance of a team-based approach to care has evolved and improved based on recent evidence," Virani said in a statement.
Comments
Post a Comment